Marriage Counselors in Montclair, CA Accepting Medicare

7 Marriage Counselors found. Showing 1 - 7

Benzion Isa Perez Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 5330 San Bernardino St, Montclair, CA 91763 Phone: 626-425-6875

Samar L Iqbal Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 5330 San Bernardino St, Montclair, CA 91763 Phone: 909-399-3751

Mrs. Elizabeth Maricella Rohskothen, MFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 5330 San Bernardino St, Montclair, CA 91763 Phone: 866-205-3595

Meredith Elena Medin, LMFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 5330 San Bernardino St, Montclair, CA 91763 Phone: 866-205-3595

Mrs. Mindy Faith Chavez, M.S., LMFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 10200 Lehigh Ave, Montclair, CA 91763 Phone: 909-445-1616    Fax: 909-445-1620

Aica Cirella Custodio Saucedo Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 5330 San Bernardino St, Montclair, CA 91763 Phone: 909-399-3700

Mary Catherine Butterly, M.F.T. Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 4959 Palo Verde St, Suite 206c-2, Montclair, CA 91763 Phone: 909-626-9401    Fax: 909-626-9382

News Archive

Cancer Research Technology grants Valirx global rights to develop VAL 201 for cancer treatment

Cancer Research Technology has signed a deal to provide biotech company ValiRx plc with the global rights to develop a promising compound to treat hormone-resistant prostate cancer.The compound, now called VAL 201, has been shown in pre-clinical tests in mice to stop growth of tumours which have been unresponsive to hormone treatments. VAL 201 blocks genes which can cause prostate cancer to develop. The compound has been shown to be effective in treating mice with breast and prostate cancer and is now rapidly progressing towards the first clinical trials in patients.

NeoPharm and Diosynth settle dispute resolution

NeoPharm, Inc. (Other OTC: NEOL.PK), announced today that it has reached a settlement agreement with Diosynth, RTP ("Diosynth"). As previously noted, NeoPharm reported that it had entered into various contractual arrangements with Diosynth to secure access to manufacturing capacity for the potential manufacture and regulatory advancement of Cintredekin Besudotox through early 2008.

CAD system makes breast MRI more effective, efficient

A computer-aided detection (CAD) system is helping radiologists to more quickly and accurately determine the sizes and locations of cancers found on breast MRI—information that could change patients' treatment, a new study shows.

IPHI receives grants to increase awareness of health-care service delivery and related policy issues

The Institute for Population Health Improvement (IPHI) has received grants totaling $423,236 from the California HealthCare Foundation and The California Endowment to increase awareness of evidence-based policies to address a wide range of health issues facing California and the nation.

Midatech Group, MonoSol Rx file patent to enable commercialization of drug delivery technology

Midatech Group Ltd., a global leader for the design, development, synthesis and manufacture of nanomedicines, and MonoSol Rx, the leader in developing and manufacturing pharmaceutical films based on its proprietary PharmFilm drug delivery technology, today announced the filing of a provisional US patent application for "Nanoparticle Film Delivery Systems." The applications submitted to the United States Patent and Trademark Office (USPTO) relate to therapeutic uses of nanoparticle-based proteins and peptides delivered in pharmaceutical films.

Read more Medical News

› Verified 4 days ago